COVID-19 llama treatment shows positive signs

COVID-19 llama treatment shows positive signs
Fifi was vaccinated with a non-infectious piece of viral protein. Researchers then recovered and isolated the strongest nanobodies in a sample of the llama’s blood. (@UniofReading)
Short Url
Updated 22 September 2021
Follow

COVID-19 llama treatment shows positive signs

COVID-19 llama treatment shows positive signs
  • Spray uses “nanobodies” produced by llamas, camels when they get an infection
  • Immunologist: “It’s very promising” and “exciting”

LONDON: A treatment derived from a llama has shown great promise in the fight against COVID-19. 

The product is a treatment made of “nanobodies,” which are simpler versions of antibodies, produced by llamas and camels when they get an infection.

Scientists have said it could be transformed into a simple nasal spray to treat early COVID-19 infection.

Prof. James Naismith described nanobodies as “fantastically exciting,” saying COVID-19-infected rodents treated with the spray had totally recovered within six days.

Public Health England has said it is looking at the “most effective SARS-CoV-2 neutralising agents” it has ever tested, and it could be used in human tests soon. 

The virus-specific nanobodies can attach to viruses and bacteria that invade the human body. It acts as a form of warning, allowing the rest of the body’s immune system to prepare to destroy the nascent infection. 

These nanobodies found by the UK researchers in llamas were shown to bind particularly tightly. “That’s where we had some help from Fifi the llama,” said Naismith.

Fifi was vaccinated with a tiny, non-infectious piece of the viral protein. The researchers then recovered and isolated the strongest nanobodies in a sample of the llama’s blood. 

From the sample of the potent nanobodies, the researchers were able to grow large quantities of its best molecules.

Prof. Sheena Cruickshank, an immunologist from the University of Manchester, said the new development is “exciting but still quite early.”

She added: “We need more data on efficacy and safety before we move to human trials. However it’s very promising nonetheless, and the fact it may be cheaper and easier to administer is a plus.

“COVID-19 will be, unfortunately, with us for a while yet, so more treatments will be needed.”

Naismith said: “Not all of the world is being vaccinated at the same speed. And there remains a risk of new variants capable of bypassing vaccine immunity emerging.”